Article
Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC.
Molecular medicine (Cambridge, Mass.) - 1 Jul 2020
Sun Dantong, Zhu Yan, Zhu Jingjuan, Tao Junyan, Wei Xiaojuan, Wo Yang, Hou Helei
Abstract excerpt
INTRODUCTION: Targeted therapy for NSCLC is rapidly evolving. EGFR-TKIs benefit NSCLC patients with sensitive EGFR mutations and significantly prolong survival. However, 20-30% of patients demonstrate primary resistance to EGFR-TKIs, which leads to the failure of EGFR-TKI treatment. The mechanisms of primary resistance to EGFR-TKIs require further study. METHODS: Targeted sequencing was used for the detection of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.